Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 03, 2023 12:03pm

173 Views

Post# 35765853

RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

I wrote: ..... In the process of achieving an Accelerated Approval a company would first seek FDA Breakthrough Therapy status ....... I now find that this is not necessarily always the case with a a company first having gained Fast Track status, but is preferable.

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth